Mays Cancer Center Conducts Only Clinical Trial in America of a Specific Drug Combination for Lethal Brain Cancer Glioblastoma

ReachMD Healthcare Image

06/09/2023

An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said.

Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu

SAN ANTONIO (May 23, 2023) — The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer Institute-Designated Cancer Centers in Texas, is the only center in America to conduct this trial.

Andrew Brenner, MD, PhD, Mays Cancer Center

Andrew Brenner, MD, PhD, professor of medicine at the UT Health Science Center San Antonio and a specialist in both breast cancer and malignancies of the brain and spinal cord, initiated the clinical trial.

“Glioblastoma is the most common and unfortunately the most aggressive primary brain tumor,” Brenner said. “The average survival for a newly diagnosed GBM is 20 months, and that’s only a four-month improvement in survival from 2005, when we began following surgery with chemotherapy and radiation.”

Glioblastoma has claimed the lives of many well-known figures. U.S. Sen. Edward M. Kennedy died of GBM in 2009. Beau Biden, son of President Joe Biden, succumbed to the disease in 2015. Sen. John McCain lost his battle with GBM in 2018.

William Kelly, MD, Mays Cancer Center

“That is the landscape in which we work,” said William Kelly, MD, Mays Cancer Center medical oncologist and assistant professor of medicine at UT Health Science Center San Antonio. “GBM comes back after treatment in almost all patients, and when it does, survival is extremely poor. There is a desperate need for more therapies to treat these patients.”

The treatment consisted of a standard-of-care chemotherapy called bevacizumab (brand name Avastin) combined with a small-molecule fatty acid synthase inhibitor called TVB-2640 (or Denifanstat). Glioblastoma tumors rely on their ability to make fatty acids for growth.

The Mays Cancer Center enrolled and treated 25 patients with GBM. Side effects such as rashes, dry eye and fatigue were mild, and researchers noted an improvement in six-month progression-free survival.

Hope tempered with realism

No current therapy improves survival in recurrent GBM. Indeed, the overall survival of participants in the Mays Cancer Center study was not statistically significant compared to historic controls (patients with high-grade GBMs who weren’t in the study and were treated with bevacizumab only).

However, the fact that the drug combination was able to arrest cancer progression for six months in a greater number of patients with high-grade GBM was noteworthy. “This gives us hope, although we are always simultaneously realistic about the disappointing history of treating these diseases,” Kelly said.

Results were published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Acknowledgments

Funding for this research was provided by a National Cancer Institute P30 grant [CA054174] as well as an endowment from the Kolitz Foundation. The Proteomics and Metabolomics Facility was supported in part by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) [RP130397] and two National Institutes of Health grants [1S10OD012304-01 and P30CA016672]. Biostatistical analysis was supported in part by a CPRIT core facility grant [RP160732]. TVB-2640 was provided by Sagimet Biosciences. The authors thank the patients for their trust and participation.


Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

William Kelly, Adolfo Enrique Diaz Duque, Joel Michalek, Brandon Konkel, Laura Caflisch, Yidong Chen, Sarath Chand Pathuri, Vinu Madhusudanannair-Kunnuparampil, John Floyd II, Andrew Brenner.

First published: May 9, 2023, Clinical Cancer Research

https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-2807/726341

In addition to their affiliation with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio, multiple authors are appointed in these academic departments and research institutes of the university’s Joe R. and Teresa Lozano Long School of Medicine: Department of Medicine, Department of Population Health Sciences, Department of Neurosurgery, Department of Cell Systems and Anatomy, and Greehey Children’s Cancer Research Institute.


The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 41,100 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.

The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit www.UTHealthSAMDAnderson.org.

Stay connected with the Mays Cancer Center on FacebookTwitterLinkedInInstagram and YouTube.

Facebook Comments

Register

We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free